misonidazole has been researched along with carboplatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ozols, RF; Poirier, MC; Reed, E; Tarone, R; Yuspa, SH | 1 |
| Chan, K; Fury, M; Humm, J; Lee, N; Ling, CC; Nehmeh, S; Schöder, H | 1 |
2 other study(ies) available for misonidazole and carboplatin
| Article | Year |
|---|---|
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; DNA Damage; DNA, Neoplasm; Drug Evaluation; Female; Humans; Middle Aged; Misonidazole; Organoplatinum Compounds; Ovarian Neoplasms | 1987 |
Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Cisplatin; Combined Modality Therapy; Fluorouracil; Humans; Laryngeal Neoplasms; Middle Aged; Misonidazole; Oropharyngeal Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Tumor Burden | 2009 |